MedTrace Logo

Drug Interaction Study Between AZD3480 and Cytochrome P450

NCT00692510 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2008-11-26

No results posted yet for this study

Summary

The purpose of the study is to evaluate if AZD3480 inhibits Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity.

Conditions

Interventions

DRUG

AZD3480

Capsule, oral, dose once daily, 7 days

DRUG

Placebo

Capsule, oral, dose once daily, 7 days

DRUG

Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)

Cocktail mix which contains the following: CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin) single dose of mix

Sponsors & Collaborators

Principal Investigators

  • Hans-Göran Hårdemark, MD · AstraZeneca R&D, Södertälje, Sweden

  • Cyril Clarke, MD · ICON Development Solutions Manchester, Manchester Science Park, Manchester, UK

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00692510 on ClinicalTrials.gov